Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:1/3/2008

the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP) and in August 2007 sold its marketing rights, with the exception of the US, to EUSA Pharma. Gentamicin Surgical Implant is currently in phase 3 development in the US for the prevention of surgical site infections. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit http://www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: VTAE ).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On February 27, 2015, the Company announced ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... 27, 2015  Acsis Inc., the market leader for ... today that John DiPalo , Acsis, Chief Strategy ... Demand Chain Executive 2015 Provider Pro to Know. ... initiatives to help prepare their companies, and customers, supply ... This year,s list of Provider Pros to Know is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... (DSMB) Authorizes Enrollment of Cervical ... Authorized Dosage Level, HOPKINTON, Mass., Sept. 24 ... independent Data,Safety Monitoring Board (DSMB) has unanimously authorized expanding ... injury (SCI) to,allow subjects with cervical SCI to be ...
... Enrollment Ahead of Schedule with Completion Expected Q2 ... Inc. (Nasdaq: ALTH ) today announced the ... safety data from the,Company,s pivotal Phase 2 PROPEL ... refractory peripheral T-cell lymphoma (PTCL). Results of,the interim ...
Cached Medicine Technology:Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 2Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 3Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 4Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 5Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5
(Date:2/27/2015)... 27, 2015 Adding to its ... pharmaceuticals, Benedict Advertising & Marketing has added Sedation ... The company’s patented NITROUSEAL® N20 closed mask and ... of sedation. , Sedation Systems, http://www.sedationsystems.com ... a new level, though it focuses primarily on ...
(Date:2/27/2015)... 27, 2015 FACE Skincare~Medical~Wellness, a ... announced a unique combination to take fifteen years ... Décolletage is a new treatment introduced that is ... specifically indicated to improve lines and wrinkles on ... person who suffers from the stubborn vertical lines ...
(Date:2/27/2015)... The Nashville periodontist office, Advanced Institute ... freshmen undergraduate students. , The Advanced Institute for Oral ... periodontal procedures such as dental implants , ... In honor of their 25th anniversary, AIOH has announced ... undergraduate students. , Students interested in the scholarship ...
(Date:2/27/2015)... 2015 Dr. Christopher Saunders, a board ... at his Chadds Ford, Pa., location. The spring special ... and will be priced at $3,950 with all fees ... it will include more than $3,000 in MedSpa services ... free Dysport. , Space is very limited, so those ...
(Date:2/27/2015)... 27, 2015 Jupiter Medical Center and ... Mount Sinai Heart New York at Jupiter Medical Center, ... South Florida. , “This innovative collaboration with Mount ... delivering unparalleled health care in our very own backyard,” ... of Jupiter Medical Center. “This kind of innovative thinking ...
Breaking Medicine News(10 mins):Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Face Skincare Announces New Combination Therapy 2Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 3Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 2Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 3Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 4Health News:Jupiter Medical Center and Mount Sinai Heart New York Announce Landmark Partnership 5
... Oct. 20 Bronstein, Gewirtz & Grossman, LLC,announces that ... United States,District Court for the District of Colorado against ... ) and various,individuals on behalf of purchasers of Spectranetics ... 4, 2008 (the "Class Period")., According to the ...
... count 12-bit ADC with Samplify,s, Prism(TM) data compression ... ... SANTA CLARA, Calif., Oct. 20 Samplify Systems, ... of true,16-channel, 12-bit, 65 Msample/sec analog-to-digital converter (ADC) ...
... Concentric Medical,Inc., the global leader in devices ... the launch of the Merci(R) Distal Access,Catheter, or ... enhanced support during minimally invasive procedures in the,brain. ... the Merci Retrieval System(TM),to remove thrombus in patients ...
... Sales Team , ... Denver, CO (PRWEB) October 20, 2008 -- OCI, ... employee benefits leaders, has added two National Sales Representatives to ... in Denver, Colorado and Scott Lenox, based in Chicago, Illinois., , ,“Kelly ...
... Injury Lawyers to Offer "Safe and Sober Free Cab Ride Home" ... ... Injury Lawyers will be adding Halloween to its list of holidays for ... will team up with Veterans Cab and Yellow Cab in Alameda and ...
... Manhattan dentist claims Pearlinbrite is more effective and precise than ... than other options. , ... New York, NY (PRWEB) ... 25 years developing Pearlinbrite, a unique in-office laser whitening system. ...
Cached Medicine News:Health News:Bronstein, Gewirtz & Grossman, LLC Announces that a Class Action has been Filed Against The Spectranetics Corporation 2Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 2Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 3Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 4Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 5Health News:Employee Benefits and Risk Management Solutions Provider OCI Appoints Two New Representatives to Its Sales Team 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 3Health News:Dr. Jan Linhart Now Offerring Unique Laser Teeth Whitening System 2
... surgery and other types of refractive surgery. ... stromal bed. Flattened tip provides easy insertion ... flap edge. Multiple ports provide multi-directional irrigation. ... 7mm from end. Two .15mm ports 2mm, ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 21G x 7/8in (.80 ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
For injecting anesthetics into the muscle cone. 25G x 1 1/2 in (.50 x 38mm)...
Medicine Products: